Cambridge managing consulting firm Scientia Advisors (my client!) has released a fascinating study about growth in the neurostimulation technology markets.
Scientia has found that these technologies–electrical devices implanted to stimulate portions of the brain, spinal cord and sacral nerve– are growing at a rate of 16 percent –and are beginning to supplant drugs as the treatment of choice for certain conditions.
The study, described in the August 21 Medical Device Daily and in a press release issued yesterday, suggests that these new technologies have fewer side effects and could help cut health care costs by doing away with the need for lifelong drug regimens. Scientia recommends that device companies become involved in this growth area.
New Cambridge Observer is a publication of the Harris Communications Group of Cambridge, MA.